Pretreatment Low Serum Sodium as a Prognostic Factor for Patients with Esophageal Cancer Treated with Radiotherapy or Chemoradiotherapy

Table 3

Cox regression analysis of clinical characteristics of overall survival of EC patients who underwent radiotherapy alone or chemoradiotherapy.

	Univariate			Multivariate
	HR	value	95% CI	HR	value	95% CI
KPS	2.207	<0.001	1.408-3.462	2.974	<0.001	1.862-4.751
70
80-90
Tumor sites
Cervical	1 (reference)
Upper	1.753	0.096	0.906-3.393
Middle	1.979	0.034	1.052-3.723
Lower	2.611	0.005	1.331-5.119
Clinical N stage
N0	1 (reference)			1 (reference)
N1	1.964	0.112	0.855-4.512	3.617	0.003	1.529-8.558
N2-3	2.690	0.019	1.175-6.158	5.205	<0.001	2.175-12.455
Clinical stage	1.371	0.038	1.017-1.848	1.473	0.017	1.070-2.026
II-III
IV
Treatment models	0.665	0.011	0.487-0.910	0.475	<0.001	0.340-0.663
Radiotherapy
Chemoradiotherapy
Serum sodium	1.966	<0.001	1.448-2.669	2.125	<0.001	1.555-2.904
>140 mmol/L
≤140 mmol/L

Abbreviation: EC: esophageal carcinoma; HR: hazard ratio; CI: confidence interval; KPS: Karnofsky performance status. . . .